Tumor-immune signatures associated with response or resistance to tislelizumab (Anti-PD-1) in esophageal squamous cell carcinoma (ESCC)
Published date:
11/09/2020
Excerpt:
In GEP-evaluable patients receiving monotherapy (n=43), DEG analysis showed toll-like receptor (TLR) signature scores, driven by TLR8, TLR6, TIRAP, and TLR4, were positively correlated with response and survival...